Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00319683
Status:
TERMINATED
Last Update Posted:
2008-12-15
First Post:
2006-04-27
Brief Title:
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced Recurrent or Metastatic Hepatocellular Carcinoma
Sponsor:
Adherex Technologies Inc
Organization:
Adherex Technologies Inc
Study Overview
Official Title:
A Phase 12 Study in Subjects With Locally Advanced Recurrent or Metastatic Hepatocellular Carcinoma Evaluating the Safety and Anti-Tumor Activity of ADH300004 Eniluracil With Escalating Doses of 5 Fluorouracil Administered Orally Once Weekly for 3 Weeks Out of Every 4 Adherex Protocol Number AHX-03-103
Status:
TERMINATED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of funds
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
5-fluorouracil 5-FU one of the most actively investigated anti-cancer drugs is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase DPD ADH300004 blocks DPD This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in subjects with locally advanced recurrent or metastatic hepatocellular carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None